Ashton Thomas Private Wealth LLC Acquires 4,306 Shares of Exelixis, Inc. $EXEL

Ashton Thomas Private Wealth LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 59.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 11,499 shares of the biotechnology company’s stock after purchasing an additional 4,306 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Exelixis were worth $507,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of EXEL. Nuveen LLC bought a new position in Exelixis in the first quarter valued at approximately $123,310,000. AQR Capital Management LLC raised its holdings in shares of Exelixis by 73.8% during the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after acquiring an additional 2,926,884 shares during the period. Invesco Ltd. raised its holdings in shares of Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after acquiring an additional 1,596,948 shares during the period. Jupiter Asset Management Ltd. lifted its position in Exelixis by 233.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company’s stock valued at $51,698,000 after acquiring an additional 980,319 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its stake in Exelixis by 935.4% in the 1st quarter. Pacer Advisors Inc. now owns 678,067 shares of the biotechnology company’s stock worth $25,034,000 after purchasing an additional 612,577 shares during the period. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Down 1.2%

EXEL opened at $38.94 on Friday. Exelixis, Inc. has a 12-month low of $31.90 and a 12-month high of $49.62. The stock has a market cap of $10.48 billion, a price-to-earnings ratio of 18.72, a PEG ratio of 0.79 and a beta of 0.38. The business has a 50 day moving average of $38.81 and a 200-day moving average of $40.21.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.84 EPS. As a group, analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $50.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Wells Fargo & Company decreased their price objective on Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a report on Tuesday, October 21st. Wall Street Zen raised Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $45.00 price target on shares of Exelixis in a research report on Tuesday, October 21st. Finally, Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $44.53.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.